Nobel Announces Private Placement Offerings

Nobel Announces Private Placement Offerings GlobeNewswire October 29, 2025 THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO, Oct. 29, 2025 (GLOBE NEWSWIRE) — Nobel Resources Corp. (TSX-V: NBLC; OTCQB: NBTRF) (the “Company” or “Nobel”) […]

Microsoft Cloud and AI Strength Drives First Quarter Results

Microsoft Corp. today announced the following results for the quarter ended September 30, 2025, as compared to the corresponding period of last fiscal year: https://mma.prnewswire.com/media/1702517/Microsoft_Company_Logo.jpg — Revenue was $77.7 billion and increased 18% (up 17% in constant currency) — Operating income was $38.0 billion and increased 24% (up 22% in constant currency) — Net income,

GRAIL to Announce Third Quarter 2025 Financial Results

Analyst Day 2025 Webcast to Begin at 11:00 a.m. ET on November 13th GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the third quarter 2025 following the close of market on Wednesday, Nov. 12, 2025.

PatientNow Acquires Recura, the AI Growth Engine Powering Practice Growth

PatientNow, the leader in practice management and growth technology for aesthetics practices, today announced the acquisition of Recura, an AI-powered growth engine designed to help practices capture, convert, and grow like never before. PatientNow has spent years as the market leader helping its customers achieve their number one goal: revenue growth. Today, their acquisition of

NewtekOne, Inc. Reports 3Q25 and Year-to-Date 2025 Basic and Diluted EPS of $0.68 and $0.67 and $1.57 and $1.54

(NasdaqGM:NEWT), BOCA RATON, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) — NewtekOne, Inc. (the “Company”) (Nasdaq: NEWT) reports its financial and operating results for the three and nine month periods ended September 30, 2025. Financial Highlights for the three and nine months ended September 30, 2025: For the three months ended September 30, 2025 (“3Q25”), basic

Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results

— Fanapt® Q3 2025 net product sales increased by 31% to $31.2 million compared to Q3 2024 — BysantiTM (milsaperidone) NDA for bipolar I disorder and schizophrenia under review by the FDA; PDUFA target action date of February 21, 2026 — Tradipitant NDA for motion sickness under review by the FDA; PDUFA target action date

NewtekOne, Inc. Reports 3Q25 and Year-to-Date 2025 Basic and Diluted EPS of $0.68 and $0.67 and $1.57 and $1.54

NewtekOne, Inc. Reports 3Q25 and Year-to-Date 2025 Basic and Diluted EPS of $0.68 and $0.67 and $1.57 and $1.54 Year-over-Year Quarterly and Year-to-Date Diluted EPS Growth Approximate 49% and 22% GlobeNewswire October 29, 2025 BOCA RATON, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) — NewtekOne, Inc. (the “Company”) (Nasdaq: NEWT) reports its financial and operating results

IM Cannabis Announces CFO Departure

IM Cannabis Corp. (NASDAQ: IMCC) (the “Company”, “IM Cannabis”, or “IMC”), a leading international medical cannabis company with operations in Israel and Germany, today announced that Uri Birenberg, the Company's Chief Financial Officer, will be stepping down from his role for personal reasons. Mr. Birenberg is expected to continue serving as Chief Financial Officer until

AMGEN ANNOUNCES WEBCAST OF 2025 THIRD QUARTER FINANCIAL RESULTS

Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2025 financial results onTuesday, November 4, 2025, after the close of theU.S.financial markets. The announcement will be followed by a conference call with the investment community at4:30 p.m. ET. Participating in the call fromAmgenwill beRobert A. Bradway, chairman and chief executive officer, and other

REGAL REXNORD REPORTS STRONG THIRD QUARTER 2025 FINANCIAL RESULTS

DATA CENTER ORDERS OF $135M IN 3Q, PLUS AN ADDITIONAL $60M IN OCTOBER Regal Rexnord Corporation (NYSE: RRX) 3Q Highlights — Diluted EPS Of $1.20, Up 10.1% Versus PY; Adjusted Diluted EPS* Of $2.51, Up 0.8% Versus PY — Daily Orders Up 9.8% Versus PY, Largely Reflecting Data Center Project Orders In AMC & PES

Scroll to Top